Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bioequivalence studies: single vs multiple dose.

V W Steinijans1, R Sauter, J H Jonkman

  • 1Department of Biometry, Byk Gulden Research Laboratories, Konstanz, FRG.

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The age and sex dynamics of heterosexual HIV transmission in Zambia: an HPTN 071 (PopART) phylogenetic and modelling study.

medRxiv : the preprint server for health sciences·2026
Same author

Stent-Assisted Angioplasty (SAA) at the Level of the Common Femoral Artery Bifurcation: Long-Term Outcomes.

Cardiovascular and interventional radiology·2020
Same author

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.

Clinical research in cardiology supplements·2019
Same author

Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.

Atherosclerosis. Supplements·2017
Same author

Erratum to: The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.

Clinical research in cardiology supplements·2017
Same author

Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.

Journal of thrombosis and haemostasis : JTH·2017

This study compares single-dose versus multiple-dose bioequivalence studies for generic drugs. It highlights the need for detailed discussion on which study type is most appropriate for regulatory submissions.

Area of Science:

  • Pharmacokinetics
  • Pharmaceutical Sciences
  • Regulatory Science

Background:

  • Generic drug substitution is increasing, making bioequivalence crucial.
  • International regulations mandate bioequivalence studies for generic drug approval.
  • The choice between single-dose and multiple-dose bioequivalence studies lacks detailed regulatory guidance.

Purpose of the Study:

  • To compare the conclusions from single-dose and multiple-dose bioequivalence studies.
  • To recommend appropriate pharmacokinetic characteristics for bioequivalence assessments.
  • To address the nuanced regulatory requirements for generic drug formulations.

Main Methods:

  • Comparative analysis of single-dose and multiple-dose bioequivalence study outcomes.
  • Utilized data from studies conducted in the same subjects for direct comparison.

Related Experiment Videos

  • Examined pharmacokinetic parameters relevant to drug absorption and disposition.

    • Main Results:

    • Single- and multiple-dose studies can yield different conclusions regarding bioequivalence.
    • Specific drug formulations, like sustained-release theophylline, may necessitate multiple-dose studies.
    • Pharmacokinetic characteristics differ based on the study design.

    Conclusions:

    • The choice of bioequivalence study design (single vs. multiple dose) is critical and impacts regulatory decisions.
    • Further discussion and clarification are needed on when multiple-dose studies are essential.
    • Standardized recommendations for pharmacokinetic characteristics in bioequivalence studies are required.